Glucotrack Stock Price, News & Analysis

Glucotrack (NASDAQ: GCTK) announced its participation in the American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23, 2025, where it will present safety and performance data from its first-in-human trial of an implantable continuous blood glucose monitoring (CBGM) system. The company's Chief Scientific Officer, Mark Tapsak, will deliver a presentation on the future of continuous glucose monitoring at the Innovation Hub. Unlike traditional CGM devices that measure glucose in interstitial fluid through skin-worn sensors, Glucotrack's innovative CBGM system is designed to be implanted in the body, directly measuring blood glucose levels without requiring external wearables, and lasting up to three years. The technology aims to minimize daily disruptions for diabetes patients while providing real-time, accurate readings.

Glucotrack (NASDAQ: GCTK) has announced the election of Victoria E. Carr-Brendel, PhD to its Board of Directors, effective May 22, 2025. Dr. Carr-Brendel brings extensive experience in medical devices and implantable technologies, currently serving on Vicarious Surgical's board and previously leading Cochlear Implants at Sonova Group. She has held leadership positions at JenaValve Technology and Boston Scientific, with a career spanning roles at Dexcom and Baxter Healthcare.

Glucotrack is developing a long-term implantable Continuous Blood Glucose Monitoring (CBGM) system designed to function for up to three years without any wearable components. The system measures glucose directly from blood, aiming to provide real-time readings without the lag time associated with traditional interstitial fluid measurements. The device is currently in investigational status under U.S. law.

Glucotrack Inc. (NASDAQ: GCTK) has announced the formation of a Patient Advisory Board (PAB) to enhance the development of its long-term implantable Continuous Blood Glucose Monitor (CBGM). Following their successful first-in-human clinical study, the PAB will include individuals with direct diabetes experience to provide insights on product development and commercialization strategies.

The company's CBGM technology is designed as a long-term implantable system with no wearable component, offering up to three years of continuous monitoring. Unlike traditional monitors that measure glucose from interstitial fluid, Glucotrack's device measures directly from blood, potentially eliminating typical lag times in readings. The inaugural PAB meeting was held on May 3, 2025, with regular meetings planned to gather ongoing patient feedback.

Glucotrack (NASDAQ: GCTK) reported its Q1 2025 financial results and corporate updates. The company is advancing its fully implantable continuous blood glucose monitor (CBGM) system, with plans to begin patient implants in Australia in Q3 2025 and expected FDA IDE approval in Q4 2025. Key developments include ethical approval in Australia for clinical studies, participation in FORGETDIABETES European research initiative, and collaboration with OneTwo Analytics for AI-driven data analysis. Financial results showed R&D expenses of $1.9M (down from $2.1M in Q1 2024), while MG&A expenses increased to $1.6M (from $0.8M). Net loss widened to $6.8M (from $2.9M), primarily due to derivative liabilities changes. The company's cash position strengthened to $9.1M as of March 31, 2025, which is expected to fund its 2025 operating plan including clinical trials.

Glucotrack (NASDAQ: GCTK) has received ethical approval from St. Vincent's Hospital Melbourne HREC for a long-term clinical study of its continuous blood glucose monitor (CBGM) for diabetes patients. The study will enroll up to 30 participants with type 1 and type 2 diabetes mellitus, initially running for 1 year with potential extension to 3 years.

The study will be led by Professor David O'Neal and Associate Professor Neale Cohen, with first patient implants expected by July 2025. Glucotrack's CBGM is a long-term implantable system designed for up to three years of continuous monitoring, featuring no wearable components and direct blood glucose measurement, unlike traditional systems that measure from interstitial fluid.

The approval follows Glucotrack's successful first-in-human study, marking a significant advancement in their clinical program.

Glucotrack (Nasdaq: GCTK) has announced its participation in the FORGETDIABETES bionic pancreas initiative, funded by the EU's Horizon 2020 program with €75 Billion. The project aims to develop a long-term automated insulin delivery system for type 1 diabetes patients.

Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.

Led by Dr. Claudio Cobelli from the University of Padova, the project includes partners from Italy, Germany, and France. The initiative aims to transform diabetes management from a constant-attention disease to a manageable lifestyle condition, similar to wearing long-term contact lenses.

Glucotrack (NASDAQ: GCTK) has partnered with OneTwo Analytics AB to analyze clinical study data for its Continuous Blood Glucose Monitor (CBGM) using AI-driven analytics. The collaboration aims to evaluate the performance and clinical value of Glucotrack's innovative CBGM technology.

Unlike traditional monitors that measure glucose in interstitial fluid, Glucotrack's CBGM is a long-term implantable device that measures glucose directly from blood, providing real-time readings without lag time. The device operates without external components and is designed to offer three years of continuous monitoring.

Through this partnership, OneTwo Analytics will apply their expertise in diabetes data analysis to identify and assess the long-term benefits of the CBGM technology. The collaboration focuses on developing a comprehensive ecosystem combining blood glucose insights, risk stratification data, patient engagement tools, and clinical dashboards.

Glucotrack (NASDAQ: GCTK) reported its full year 2024 financial results, marking a transformative year as the company advanced from preclinical to clinical stage. The company successfully completed its first human clinical study of the continuous blood glucose monitor (CBGM), which met its primary endpoint with no serious adverse events.

Key financial highlights include:

• R&D expenses increased to $9.5M (vs $4.7M in 2023)
• Marketing and administrative expenses rose to $5.1M (vs $2.4M in 2023)
• Net loss widened to $22.6M (vs $7.1M in 2023)
• Cash position of $5.6M as of December 31, 2024
• Secured $16.3M through multiple funding rounds from November 2024 through March 2025

The company expects FDA IDE approval for their CBGM technology in Q4 2025 and plans to commence a long-term multicenter feasibility study in Australia in Q2 2025. Their CBGM technology will be the first fully implantable system with a multi-year monitoring capability and real-time measuring features.

Glucotrack (NASDAQ: GCTK) has announced it will present safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Amsterdam.

The company's CBGM technology is a long-term implantable device designed to last three years with no on-body external component. Unlike traditional monitors that measure glucose in interstitial fluid, Glucotrack's system measures glucose directly from the blood, potentially offering greater accuracy and real-time monitoring.

The presentation will feature results from an early feasibility study evaluating the intravascular CBGM in adults with diabetes mellitus. The study aims to demonstrate the safety, feasibility, and performance of the device. The company plans to advance its clinical program with an upcoming chronic implant study.